Literature DB >> 7520468

Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein.

I Couillin1, B Culmann-Penciolelli, E Gomard, J Choppin, J P Levy, J G Guillet, S Saragosti.   

Abstract

Human immunodeficiency virus (HIV) induces strong responses from human histocompatibility leukocyte antigen (HLA) class I-restricted cytotoxic T lymphocytes (CTL). In a previous report we identified an immunodominant region (amino acids 73-144) in the NEF protein that was recognized by CD8+ class I-restricted CTL of most asymptomatic individuals. Analysis of the 73-144 region by peptide sensitization, experiments using overlapping peptides corresponding to the LAI isolate identified the peptide sequences located between residues 73 and 82 or 84 and 92 and the peptide sequence between residues 134 and 144 as cognate peptides for HLA-A11- and HLA-B18-restricted epitopes, respectively. This report describes the variable demonstrable reactivities of CTL obtained from HLA-A11 or HLA-B18 seropositive, asymptomatic patients who all had a response to the virus NEF protein, but who did not always recognize appropriate cognate peptides. The high mutation rate of HIV probably facilitates the selection of mutants that can avoid the cellular immune response. We therefore analyzed the variability of these epitopes restricted by HLA-A11 and HLA-B18. We sequenced several viral isolates from HLA-A11 and HLA-B18 donors who recognized certain HLA-peptide complexes and from those who did not. A CTL sensitization assay was used to show that some mutations led to a great reduction in CTL activity in vitro. This might be due to failure of the mutated epitope to bind major histocompatibility complex class I molecule. A simple assay was used to detect peptides that promoted the assembly of class I molecules. Some of these mutations at major anchor positions prevented HLA-A11/peptide binding, and consequently impaired recognition of the HLA-peptide complex by the T cell receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520468      PMCID: PMC2191631          DOI: 10.1084/jem.180.3.1129

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes.

Authors:  L C Dai; K West; R Littaua; K Takahashi; F A Ennis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

2.  Nomenclature for factors of the HLA system, 1991. The WHO Nomenclature Committee for factors of the HLA system.

Authors: 
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides.

Authors:  M DiBrino; K C Parker; J Shiloach; M Knierman; J Lukszo; R V Turner; W E Biddison; J E Coligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

4.  An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins.

Authors:  Q J Zhang; R Gavioli; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

5.  In vitro human cytotoxic T cell responses against influenza A virus can be induced and selected by synthetic peptides.

Authors:  F Martinon; E Gomard; C Hannoun; J P Lévy
Journal:  Eur J Immunol       Date:  1990-10       Impact factor: 5.532

6.  Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells.

Authors:  J Sloan-Lancaster; B D Evavold; P M Allen
Journal:  Nature       Date:  1993-05-13       Impact factor: 49.962

7.  Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins.

Authors:  S Lamhamedi-Cherradi; B Culmann-Penciolelli; B Guy; M P Kiény; F Dreyfus; A G Saimot; D Sereni; D Sicard; J P Lévy; E Gomard
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

8.  Monoclonal antibodies as a tool for phylogenetic studies of major histocompatibility antigens and beta 2-microglobulin.

Authors:  J L Teillaud; D Crevat; P Chardon; J Kalil; C Goujet-Zalc; G Mahouy; M Vaiman; M Fellous; D Pious
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

9.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

Authors:  B D Walker; C Flexner; K Birch-Limberger; L Fisher; T J Paradis; A Aldovini; R Young; B Moss; R T Schooley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules.

Authors:  B Culmann; E Gomard; M P Kiény; B Guy; F Dreyfus; A G Saimot; D Sereni; J P Lévy
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

View more
  56 in total

1.  Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes.

Authors:  J T Voeten; T M Bestebroer; N J Nieuwkoop; R A Fouchier; A D Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift.

Authors:  R Khanna; R W Slade; L Poulsen; D J Moss; S R Burrows; J Nicholls; J M Burrows
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.

Authors:  Fred W Peyerl; Heidi S Bazick; Michael H Newberg; Dan H Barouch; Joseph Sodroski; Norman L Letvin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variants.

Authors:  R Khanna; S R Burrows; S L Silins; D J Moss; L M Poulsen; J M Burrows
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 6.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

7.  Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Authors:  Hanne Gahéry-Ségard; Gilles Pialoux; Suzanne Figueiredo; Céline Igéa; Mathieu Surenaud; Jessintha Gaston; Helene Gras-Masse; Jean-Paul Lévy; Jean-Gérard Guillet
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus.

Authors:  D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution.

Authors:  J M Burrows; S R Burrows; L M Poulsen; T B Sculley; D J Moss; R Khanna
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro.

Authors:  E G M Berkhoff; A C M Boon; N J Nieuwkoop; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.